BR112017009237A2 - composições de éster de forbol e métodos para tratar ou reduzir a duração de citopenia - Google Patents

composições de éster de forbol e métodos para tratar ou reduzir a duração de citopenia

Info

Publication number
BR112017009237A2
BR112017009237A2 BR112017009237A BR112017009237A BR112017009237A2 BR 112017009237 A2 BR112017009237 A2 BR 112017009237A2 BR 112017009237 A BR112017009237 A BR 112017009237A BR 112017009237 A BR112017009237 A BR 112017009237A BR 112017009237 A2 BR112017009237 A2 BR 112017009237A2
Authority
BR
Brazil
Prior art keywords
cytopenia
methods
duration
phorbol ester
treating
Prior art date
Application number
BR112017009237A
Other languages
English (en)
Inventor
Tao Han Zheng
Original Assignee
Biosuccess Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosuccess Biotech Co Ltd filed Critical Biosuccess Biotech Co Ltd
Publication of BR112017009237A2 publication Critical patent/BR112017009237A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Peptides Or Proteins (AREA)

Abstract

a presente invenção refere-se aos métodos e composições contendo um éster de forbol, ou um derivado de um éster de forbol em combinação com g-csf ou em combinação com epo, para o tratamento de citopenia em indivíduos mamíferos. as composições e métodos também reduzem a duração de citopenia tal como neutropenia, trombocitopenia, e/ou anemia.
BR112017009237A 2014-11-03 2015-11-03 composições de éster de forbol e métodos para tratar ou reduzir a duração de citopenia BR112017009237A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462074133P 2014-11-03 2014-11-03
PCT/US2015/058732 WO2016073416A1 (en) 2014-11-03 2015-11-03 Phorbol ester compositions and methods for treating or reducing the duration of cytopenia

Publications (1)

Publication Number Publication Date
BR112017009237A2 true BR112017009237A2 (pt) 2017-12-26

Family

ID=54479028

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017009237A BR112017009237A2 (pt) 2014-11-03 2015-11-03 composições de éster de forbol e métodos para tratar ou reduzir a duração de citopenia

Country Status (18)

Country Link
US (3) US11260041B2 (pt)
EP (1) EP3215177B1 (pt)
JP (1) JP6755865B2 (pt)
KR (1) KR102527457B1 (pt)
CN (2) CN114887038A (pt)
AU (1) AU2015343375B2 (pt)
BR (1) BR112017009237A2 (pt)
CA (1) CA2965848A1 (pt)
HK (1) HK1244203A1 (pt)
IL (2) IL285900B2 (pt)
MA (1) MA40904A (pt)
MX (2) MX2017005499A (pt)
MY (1) MY185869A (pt)
PH (1) PH12017500814A1 (pt)
RU (2) RU2730998C2 (pt)
SG (3) SG10201911605TA (pt)
TW (1) TWI725947B (pt)
WO (1) WO2016073416A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
CN109662968B (zh) * 2017-10-13 2021-05-18 上海奥奇医药科技有限公司 含A-失碳-5α雄甾烷化合物的升白制剂及其应用
CN108653265A (zh) * 2018-04-26 2018-10-16 五邑大学 一种复合抗癌药物
KR102178075B1 (ko) * 2020-07-31 2020-11-13 (주)쓰리에이씨 마스크 수명 인디케이터 및 이를 포함하는 마스크

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080784A (en) * 1986-06-11 2000-06-27 Procyon Pharmaceuticals, Inc. Protein kinase C modulators N
AU5277902A (en) * 1995-03-03 2002-08-15 Trustees Of Boston University Compositions for the treatment of blood disorders
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US6063814A (en) * 1997-04-14 2000-05-16 Chang; Richard L. Phorbol esters as anti-neoplastic and white blood cell elevating agents
US7345031B2 (en) * 2000-04-12 2008-03-18 International Medical Innovations, Inc. Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation and use
US7078376B1 (en) * 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
US7407026B2 (en) * 2000-10-11 2008-08-05 Ford Global Technologies, Llc Control system for a hybrid electric vehicle to anticipate the need for a mode change
US20040091503A1 (en) * 2002-08-20 2004-05-13 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
MY186986A (en) * 2007-01-31 2021-08-26 Biosuccess Biotech Co Ltd Compositions and methods of use of phorbol esters
US11564901B2 (en) * 2007-01-31 2023-01-31 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters
US9636317B2 (en) * 2007-01-31 2017-05-02 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters
EA201190079A1 (ru) * 2009-01-16 2013-02-28 Тева Фармасьютикал Индастриз, Лтд. Новые стабильные составы рекомбинантного альбумина человека-гранулоцитарного колониестимулирующего фактора человека
CN102380090A (zh) * 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 G-csf二聚体在治疗嗜中性粒细胞减少症中的应用
CA3077480C (en) * 2012-01-18 2023-03-14 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters in the treatment of parkinson's disease

Also Published As

Publication number Publication date
JP2017534632A (ja) 2017-11-24
IL285900B (en) 2022-11-01
EP3215177B1 (en) 2022-05-11
HK1244203A1 (zh) 2018-08-03
MX2022001377A (es) 2022-04-01
KR20170072347A (ko) 2017-06-26
IL285900B2 (en) 2023-03-01
RU2017119183A3 (pt) 2019-05-16
US20220133675A1 (en) 2022-05-05
JP6755865B2 (ja) 2020-09-16
EP3215177A1 (en) 2017-09-13
SG11201703530TA (en) 2017-05-30
SG10201903942UA (en) 2019-05-30
MX2017005499A (es) 2017-08-04
AU2015343375A1 (en) 2017-05-25
TW201630597A (zh) 2016-09-01
CN107206053A (zh) 2017-09-26
CN107206053B (zh) 2022-06-07
MA40904A (fr) 2017-09-12
CN114887038A (zh) 2022-08-12
SG10201911605TA (en) 2020-01-30
KR102527457B1 (ko) 2023-04-28
CA2965848A1 (en) 2016-05-12
TWI725947B (zh) 2021-05-01
RU2020125187A (ru) 2020-08-27
US11260041B2 (en) 2022-03-01
PH12017500814A1 (en) 2017-10-02
MY185869A (en) 2021-06-14
RU2017119183A (ru) 2018-12-05
IL251937B (en) 2021-09-30
RU2730998C2 (ru) 2020-08-26
IL251937A0 (en) 2017-06-29
WO2016073416A1 (en) 2016-05-12
AU2015343375B2 (en) 2021-07-01
US20170224648A1 (en) 2017-08-10
NZ731599A (en) 2021-04-30
US20160120836A1 (en) 2016-05-05
IL285900A (en) 2021-09-30

Similar Documents

Publication Publication Date Title
PH12016501512A1 (en) Treatment for resistant acne
CL2018000429A1 (es) Moduladores de la expresión de kras
BR112016003201A2 (pt) inibidores de grp94 seletivos e usos dos mesmos
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
PH12015502216A1 (en) Compositions and methods for improving the health of aquatic animals
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
UY36868A (es) Composiciones para tratamiento de enfermedades mediadas por interleuquina 5 (il-5)
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
EA030204B8 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
SG10201900564WA (en) Methods for treating cancer
BR112018009941A2 (pt) composição reguladora de crescimento vegetal com efeito sinergético
BR112017010669A2 (pt) composição, método para reduzir o número de patógenos sobre uma superfície e método para reduzir o número de patógenos em um volume de um produto alimentício
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
BR112017009237A2 (pt) composições de éster de forbol e métodos para tratar ou reduzir a duração de citopenia
BR112017006779A2 (pt) composição farmacêutica oral de baixa dose seu processo de preparação e método de tratamento
MX2017003550A (es) Uso de cisteamina en tratamiento de infecciones causadas por levaduras/mohos.
BR112018008931A2 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?
EP3221351A4 (en) Methods and compositions for cancer treating conditions relating to over expressions of epha2
BR112016001677A2 (pt) Método para a redução ou inibição da progressão de um espessamento da pele em um indivíduo com essa necessidade e método para a regulação de uma resposta de egfr em um indivíduo com essa necessidade
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
BR112017007971A2 (pt) composição para a aquicultura, composição alimentar para aquicultura, banho de imersão para espécies aquáticas e uso de um composto protetor externo para espécies aquáticas
MX356816B (es) Proceso y composición para pigmentar piel de ave.
EP2910247A4 (en) COMPOSITIONS FOR PREVENTING OR TREATING ALLERGIC SKIN DISORDERS CONTAINING GPCR19 AGENTS AS ACTIVE INGREDIENTS

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]